A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT)....
Saved in:
Main Authors: | Zhen-Yu Xiong, Yao-Jia Shen, Shi-Zhong Zhang, Hong-Hu Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Hematology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2335856 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
by: Xiaoxia Wu, et al.
Published: (2024-09-01) -
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients
by: Jeffrey Baron, et al.
Published: (2024-01-01) -
Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia
by: Qian Liu, et al.
Published: (2024-12-01) -
Chronic myeloid leukemia in an asymptomatic young patient: a rare case report
by: Urja Bhatt, et al.
Published: (2024-11-01) -
High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR‐ABL1‐like acute lymphoblastic leukemia
by: Jae Wook Lee, et al.
Published: (2020-07-01)